The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi pathway. When miRNA acts as the guide for RNAi, only a ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease. The “select” ...

Researchers have discovered RNA mechanisms that may lead to more effective, durable and targeted treatments for conditions like high cholesterol, liver diseases and cancers. RNA interference (RNAi) ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

An RNA interference therapy, targeting ANGPTL3 in the liver, drastically reduced fasting triglycerides in people with mixed hyperlipidemia, the ARCHES-2 trial showed. Used atop usual statins and other ...

New Transfection Systems Tackle Delivery Issues and Off-Target Effects Will RNAi-based therapeutics provide the next class of blockbuster drugs? If pharma’s acquisition spree of companies with ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...